Edition:
United Kingdom

Biofrontera AG (B8FGn.DE)

B8FGn.DE on Xetra

6.70EUR
23 Aug 2019
Change (% chg)

€-0.02 (-0.30%)
Prev Close
€6.72
Open
€6.76
Day's High
€6.79
Day's Low
€6.66
Volume
17,408
Avg. Vol
89,093
52-wk High
€8.07
52-wk Low
€4.78

Summary

Name Age Since Current Position

Ulrich Granzer

2016 Chairman of the Supervisory Board

Hermann Luebbert

63 2005 Chairman of the Management Board, Chief Executive Officer

Juergen Baumann

65 2016 Vice Chairman of the Supervisory Board

Thomas Schaffer

2013 Chief Financial Officer, Member of the Management Board

Christoph Duenwald

2016 Member of the Management Board, Chief Commercial Officer

John Borer

2016 Member of the Supervisory Board

Reinhard Eyring

2018 Member of the Supervisory Board

Franca Ruhwedel

2019 Member of the Supervisory Board

Kevin Weber

2016 Member of the Supervisory Board

Anke zur Muehlen

Investor Relations Contact Officer

Biographies

Name Description

Ulrich Granzer

Dr. Ulrich Granzer, Ph.D., has been Chairman of the Supervisory Board of Biofrontera AG since June 1, 2016. He was Member of the Supervisory Board from 2003 to June 1, 2016. He is Member of the Audit Committee, Chairman of the R&D & Market Access Committee and the Nomination Committee at the Company. He is also Owner and Managing Director of Ulrich Granzer Regulatory Consulting & Services.

Hermann Luebbert

Prof. Dr. Hermann Luebbert, Ph.D., has been Chairman of the Management Board and Chief Executive Officer at Biofrontera AG since 2005. After eight years of academic research at the Universitaet zu Koeln and the California Institute of Technology, he spent ten years gaining experience in global research management at Sandoz and Novartis Pharma AG, prior to establishing Biofrontera AG in 1997. Prof. Dr. Luebbert was awarded the habilitation at the ETH (Eidgenoessische Technische Hochschule) Zuerich and holds the chair of Animal Physiology at Ruhr-Universitaet Bochum. He studied Biology in Koeln, where he completed a Doctorate in Philosophy in 1984.

Juergen Baumann

Mr. Juergen Baumann has been Vice Chairman of the Supervisory Board of Biofrontera AG since June 1, 2016. He was Chairman of the Supervisory Board at the Company from September 4, 2007 to June 1, 2016. He is Chairman of the Audit Committee He has been active in various positions for 29 years at Schwarz Pharma AG. When he joined Schwarz Pharma in 1978, his initial function was in the area of company-planning and -organization. Later, by then head of the Marketing Services area, he was first responsible for building the business in the East-German states and later he managed the Business Development and International Marketing section. From 1998 to 2000, he headed the business of Schwarz Pharma AG in Europe (except Germany). He is a management consultant.

Thomas Schaffer

Mr. Thomas Schaffer has been Chief Financial Officer and Member of the Management Board at Biofrontera AG since June 3, 2013. Mr. Schaffer has been esponsible for Finance and Administration, Controlling and Investor Relation. Mr. Schaffer started his career in various functions in Finance and Controlling at Siemens Semiconductor, where he reached the position of Vice President and CFO of the Security & Chipcard ICs. After four years as Managing Director and CFO of Infineon Ventures GmbH, he continued as Vice President and CFO of the Specialty DRAM Division of Qimonda AG and became Managing Director of Qimonda Solar GmbH. CFO positions at Heptagon Oy, Finland/Switzerland, and Ubidyne Inc., Delaware, USA, completed his international experience. Mr. Schaffer played roles in reaching corporate milestones for the companies he worked for, including capital raises, debt financings, corporate restructurings, M&A, and IPOs.

Christoph Duenwald

Mr. Christoph Duenwald has been Member of the Management Board, Chief Commercial Officer at Biofrontera AG since April 15, 2016. Previously he served as Chief Commercial Officer at the Company from July 22, 2015 till April 15, 2016. He also held management positions at Bayer Healthcare and Allergan.

John Borer

Mr. John J. Borer has been Member of the Supervisory Board of Biofrontera AG since June 1, 2016. He is Member of the Audit Committee and the Nomination Committee at the Company. He is Head of Investment Banking at The Benchmark Company LLC, New York. He was formerly the CEO and Head of Investment Banking at Rodman & Renshaw, and has held senior positions at Pacific Business Credit and Barclays American Business Credit. He holds a Doctor of Law degree (J.D.) from Loyola Law School in Los Angeles and Bachelor of Science in Agricultural Economics from University of California.

Reinhard Eyring

Mr. Reinhard Eyring has been Member of the Supervisory Board of Biofrontera AG since February 1, 2018. He is Partner of Ashurst LLP law firm, Frankfurt/Main and has also served at DESTAG Deutsche Steinindustrie AG as Supervisory Board Chairman and at Vanguard AG as Supervisory Board Chairman.

Franca Ruhwedel

Kevin Weber

Mr. Kevin D. Weber has been Member of the Supervisory Board of Biofrontera AG since June 1, 2016. He is Member of the R&D & Market Access Committee at the Company. He has acted as Chief Executive Officer of Paraffin International Inc. He has experience in marketing and global operations and strategy, and has held senior roles at Depomed, Hyperion Therapeutics, and Medicis Pharmaceuticals. He is also Principal of Skysis, LLC., Scottsdale, AZ, the United States. He holds a Bachelor of Arts degree in Management and Marketing from Western Michigan University.

Anke zur Muehlen

Basic Compensation